Centessa Pharmaceuticals Completes Acquisition by Eli Lilly, Shares to Delist
Summary
Centessa Pharmaceuticals has finalized its acquisition by Eli Lilly, leading to its delisting from Nasdaq and a change in control, with shareholders receiving cash and CVRs.
Key Events
-
Acquisition Finalized
Eli Lilly and Company's subsidiary completed the acquisition of Centessa Pharmaceuticals plc on June 24, 2026.
-
Shareholder Payout
Holders of Centessa shares will receive $38.00 in cash per share plus one non-transferable Contingent Value Right (CVR) for up to an additional $9.00 per share.
-
Nasdaq Delisting
Centessa has requested Nasdaq to halt trading and delist its American Depositary Shares (ADSs), with reporting obligations to be suspended.
-
Change in Control and Leadership
Centessa is now a wholly-owned subsidiary of Eli Lilly, resulting in a complete change of its board of directors and executive officers.
Analysis
This filing marks the definitive completion of Centessa Pharmaceuticals' acquisition by Eli Lilly and Company. As a result, Centessa ceases to be an independent public entity, its shares will be delisted from Nasdaq, and its reporting obligations will be suspended. Shareholders will receive the previously announced cash consideration and contingent value rights. This event fundamentally alters the investment thesis for Centessa, as it transitions from a publicly traded company to a wholly-owned subsidiary.
At the time of this filing, CNTA was trading at $40.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $12.39 to $40.56. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.